Project Grant R01CA283369
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$432K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $225,101 to Baylor College of Medicine to conduct research on how the MYCN oncogene drives an immune-suppressive tumor microenvironment in neuroblastoma. The project aims to determine how MYCN reprograms T cell metabolism to impair anti-tumor immune responses, and elucidate how MYCN-induced lipogenesis contributes to this suppressive tumor immune environment. The findings from...
This $1,373,418 federal Project Grant award, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program), supports research into the role of the NRF2 oncogene in the metastatic spread of high-risk hepatoblastoma (HB), the most common pediatric liver cancer. The Baylor College of Medicine, the prime awardee, aims to thoroughly characterize the molecular mechanisms by which NRF2 drives HB cell dissemination, invasion, and metastasis. The 5-year project involves in vitro...
This federal Project Grant award for $635,173 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research on mechanisms of immunosuppression in MYCN-driven neuroblastoma. The key objectives are to characterize the immune cell types recruited to the tumor microenvironment, elucidate how the chemokine CKLF1 modulates CD4+ cells to induce immunosuppression, and...
This $576,659 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to investigate tumor and host immune signatures associated with disparities in outcomes following GD2 immunotherapy for patients with high-risk neuroblastoma. The primary awardee, Emory University, is collaborating with sub-awardees Dana-Farber Cancer Institute and University of Florida to: Perform tumor-based single cell genomic, proteomic, and...
The National Cancer Institute (NCI) awarded a $377,102 Project Grant (CFDA 93.398 - Cancer Research Manpower) to The Johns Hopkins University on September 6, 2024. The award will fund a research project titled "Defining Protein Translation Dynamics in Cancers with Differential MYC Expression" over a period ending on March 31, 2027. The research aims to investigate the effects of MYC gene overexpression on protein translation dynamics, ribosome collision frequency, and sensitivity to...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $718,113 to St. Jude Children's Research Hospital to conduct research focused on understanding the interactions between MYC oncogenes, core regulatory circuitry transcription factors (CRC TFs), and epigenetic modifiers in neuroblastoma pathogenesis. The goal is to identify targetable epigenetic modifiers, such as histone deacetylases (HDAC) and histone lysine demethylase 4...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Emory University to conduct research aimed at modeling and targeting intrinsic and extrinsic features of MYC-driven osteosarcoma. The $452,549 award, with a project period from March 1, 2025 to February 28, 2030, will support a comprehensive characterization of the molecular and cellular signatures of MYC-amplified osteosarcoma tumors, including their impact on the...
This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct advanced genetic engineering research to unravel tumor-specific B cell responses. The goal is to rapidly generate tumor-specific B cells that can be used to study the role of antigen-specific B cells in tumor progression, with the ultimate aim of developing innovative...
This $377,870 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development and validation of novel synthetic transcriptional repressors (STRs) capable of directly inhibiting the oncogenic transcription factor MYC. The grant aims to: 1) Optimize STR structures for high-affinity and specific binding to MYC target DNA sequences, 2) Enhance cellular and pharmacologic delivery of STRs while mapping their effects on epigenetic and...